X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
MSP-2017 (etripamil) is a fast-acting, intranasally administered calcium-channel blocker, which is being evaluated for the treatment of Paroxysmal Supraventricular Tachycardia.
Lead Product(s): Etripamil
Therapeutic Area: Cardiology/Vascular Diseases Product Name: MSP-2017
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 28, 2024
Details:
Milestone intends to use the net proceeds from the Offering to continue the development of Cardamyst (etripamil) in its lead indication of paroxysmal supraventricular tachycardia.
Lead Product(s): Etripamil
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Cardamyst
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Piper Sandler & Co
Deal Size: $30.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 29, 2024
Details:
Milestone intends to use the net proceeds from the offering to continue the development of MSP-2017 (etripamil) in its lead indication of paroxysmal supraventricular tachycardia.
Lead Product(s): Etripamil
Therapeutic Area: Cardiology/Vascular Diseases Product Name: MSP-2017
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Piper Sandler
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering February 28, 2024
Details:
MSP-2017 (etripamil) is a fast-acting, intranasally administered calcium-channel blocker, which is being evaluated for the treatment of Paroxysmal Supraventricular Tachycardia.
Lead Product(s): Etripamil
Therapeutic Area: Cardiology/Vascular Diseases Product Name: MSP-2017
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 26, 2024
Details:
MSP-2017 (etripamil) is a novel calcium channel blocker. It is under phase 3 clinical development for the treatment of paroxysmal supraventricular tachycardia.
Lead Product(s): Etripamil
Therapeutic Area: Cardiology/Vascular Diseases Product Name: MSP-2017
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 26, 2023
Details:
MSP-2017 (etripamil) is Milestone's lead investigational product. It is a novel calcium channel blocker nasal spray being developed for elevated and often highly symptomatic heart-rate attacks associated with PSVT and atrial fibrillation with a rapid ventricular rate.
Lead Product(s): Etripamil
Therapeutic Area: Cardiology/Vascular Diseases Product Name: MSP-2017
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 24, 2023
Details:
The net proceeds from the financing will be used to support the advancement of MSP-2017 (etripamil), a novel calcium channel blocker nasal spray, for paroxysmal supraventricular tachycardia.
Lead Product(s): Etripamil
Therapeutic Area: Cardiology/Vascular Diseases Product Name: MSP-2017
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: RTW Investments
Deal Size: $125.0 million Upfront Cash: Undisclosed
Deal Type: Financing March 28, 2023
Details:
MSP-2017 (etripamil) is a calcium channel antagonist potentially for the treatment of paroxysmal supraventricular tachycardia. It is designed to be a rapid-response therapy for elevated and often highly symptomatic heart rate attacks associated with PSVT and AFib-RVR.
Lead Product(s): Etripamil
Therapeutic Area: Cardiology/Vascular Diseases Product Name: MSP-2017
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 06, 2023
Details:
MSP-2017 (etripamil), a new chemical entity, is a novel calcium channel blocker designed to be a rapid-response therapy for episodic cardiovascular conditions.
Lead Product(s): Etripamil
Therapeutic Area: Cardiology/Vascular Diseases Product Name: MSP-2017
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 25, 2022
Details:
MSP-2017 (etripamil), is a novel calcium channel blocker designed to be a rapid-response therapy for episodic cardiovascular conditions. As a nasal spray that is self-administered by the patient.
Lead Product(s): Etripamil
Therapeutic Area: Cardiology/Vascular Diseases Product Name: MSP-2017
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Medpace, Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 17, 2022
Details:
Of 198 eligible NODE-301 patients, 169 (85%) enrolled in NODE-302 and 105 (62%) experienced a perceived episode of PSVT, self-administered etripamil, and were included in the safety population.
Lead Product(s): Etripamil
Therapeutic Area: Cardiology/Vascular Diseases Product Name: MSP-2017
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 30, 2022
Details:
As a nasal spray that is self-administered by the patient, etripamil has the potential to shift the current treatment experience for many patients from the emergency department to a medically-unsupervised setting.
Lead Product(s): Etripamil
Therapeutic Area: Cardiology/Vascular Diseases Product Name: MSP-2017
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 14, 2022
Details:
Etripamil nasal spray is a novel calcium channel blocker designed to be a rapid-response therapy for episodic cardiovascular conditions, especially Paroxysmal supraventricular tachycardia (PSVT).
Lead Product(s): Etripamil
Therapeutic Area: Cardiology/Vascular Diseases Product Name: MSP-2017
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 15, 2021
Details:
Under the terms of the agreement, Milestone will grant Ji Xing an exclusive license to develop and, if regulatory approval is obtained, commercialize etripamil in patients with PSVT in Greater China.
Lead Product(s): Etripamil
Therapeutic Area: Cardiology/Vascular Diseases Product Name: MSP-2017
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Xing Pharmaceuticals
Deal Size: $127.5 million Upfront Cash: $20.0 million
Deal Type: Collaboration May 17, 2021
Details:
Milestone intends to use the net proceeds from the offering primarily to fund the clinical development of its lead product candidate etripamil, and for general corporate purposes.
Lead Product(s): Etripamil
Therapeutic Area: Cardiology/Vascular Diseases Product Name: MSP-2017
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Jefferies and Piper Sandler
Deal Size: $45.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering October 23, 2020
Details:
Recently completed NODE-301 and ongoing NODE-301B studies can be used as two efficacy studies supporting a future NDA submission (target p-values of <0.05).
Lead Product(s): Etripamil
Therapeutic Area: Cardiology/Vascular Diseases Product Name: MSP-2017
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 23, 2020
Details:
Etripamil (70mg) did not achieve its primary endpoint of time to conversion of SVT to sinus rhythm (SR) compared to placebo over the five hour period following study drug administration.
Lead Product(s): Etripamil
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 23, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
